Phenotypes Associated with This Genotype

Genotype
MGI:5634095

• Allelic Composition: Tg(Mbp-SNCA)1Ema/0
• Genetic Background: involves: C57BL/6 * DBA/2

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

behavior/neurological

tremors ( J:102867 )

• mild tremors that initiate at 12 months of age

abnormal motor coordination/balance ( J:102867 )

• 4 month old mice show deficits in the pole test which are increased at 6 months of age

impaired coordination ( J:102867 )

• 4 month old mice are impaired on the rotarod

nervous system

brain inflammation ( J:207162 )

• mice show an increase in expression of multiple inflammatory cytokines and chemokines, indicating neuroinflammation

• treatment with antidepressant drugs modulates cytokine and chemokine expression

abnormal astrocyte morphology ( J:207162 )

• accumulation of alpha-synuclein within astrocytes

astrocytosis ( J:102867 , J:207162 )

• astrogliosis in the corpus callosum (J:102867)

• astrogliosis in the corpus callosum, hippocampus and basal ganglia (J:207162)

• treatment with antidepressant drugs reduces astrogliosis in the hippocampus and the basal ganglia, but not in the corpus callosum (J:207162)

abnormal oligodendrocyte morphology ( J:207162 )

• oligodendroglial accumulation of alpha-synuclein in frontal cortex, basal ganglia, and corpus callosum

abnormal neurite morphology ( J:102867 )

• decrease in neurite density in the neocortex

abnormal axon morphology ( J:102867 )

• axonal alternations in the neocortex, including decreased neurite density and formation of irregular and enlarged axons

alpha-synuclein inclusion body ( J:102867 , J:207162 )

• inclusions of human alpha-synuclein aggregates are seen in oligodendrocytes at 6 months of age (J:102867)

• oligodendroglial accumulation of alpha-synuclein in frontal cortex, basal ganglia, and corpus callosum (J:207162)

• accumulation of alpha-synuclein within astrocytes (J:207162)

• treatment with antidepressant drugs, fluoxetine, olanzapine, or amitriptyline, reduces intracellular alpha-synuclein accumulation in the basal ganglia and in astrocytes (J:207162)

neurodegeneration ( J:102867 )

• neurodegeneration in the neocortex

• 45% reduction in the density of TH+ fibers in the basal ganglia

demyelination ( J:102867 )

• attenuation of myelin staining in the corpus callosum

homeostasis/metabolism

abnormal physiological response to xenobiotic ( J:207162 )

• treatment with fluoxetine for 5 weeks, but not olanzapine or amitriptyline, increase hippocampal neurogenesis

immune system

brain inflammation ( J:207162 )

• mice show an increase in expression of multiple inflammatory cytokines and chemokines, indicating neuroinflammation

• treatment with antidepressant drugs modulates cytokine and chemokine expression

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
multiple system atrophy		DOID:4752		J:207162